187 related articles for article (PubMed ID: 37453907)
1. Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use.
Uttaro E; Young MR; Falvey J; Corvelli JM; Acquisto NM
Transfus Apher Sci; 2023 Oct; 62(5):103759. PubMed ID: 37453907
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
3. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
5. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
7. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
9. Utilization and safety of off-label prothrombin complex concentrate (four-factor prothrombin complex concentrate) in a surgical population.
Sandquist K; Kaucher K; Newell J; Sarangarm P; Burnett A
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):124-128. PubMed ID: 38477833
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 4-Factor Prothrombin Complex Concentrate With Frozen Plasma for Management of Hemorrhage During and After Cardiac Surgery: A Randomized Pilot Trial.
Karkouti K; Bartoszko J; Grewal D; Bingley C; Armali C; Carroll J; Hucke HP; Kron A; McCluskey SA; Rao V; Callum J
JAMA Netw Open; 2021 Apr; 4(4):e213936. PubMed ID: 33792729
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
12. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
13. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
[TBL] [Abstract][Full Text] [Related]
15. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
[TBL] [Abstract][Full Text] [Related]
16. Four-factor prothrombin complex concentrate use for on-label versus off-label indications: a retrospective cohort study.
Adkins BD; Shaim H; Abid A; Gonzalez A; DeAnda A; Yates SG
J Thromb Thrombolysis; 2023 Jan; 55(1):74-82. PubMed ID: 35699871
[TBL] [Abstract][Full Text] [Related]
17. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
[TBL] [Abstract][Full Text] [Related]
19. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
[TBL] [Abstract][Full Text] [Related]
20. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Pabinger I; Brenner B; Kalina U; Knaub S; Nagy A; Ostermann H;
J Thromb Haemost; 2008 Apr; 6(4):622-31. PubMed ID: 18208533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
